EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Sept. 12, 2006--SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today the presentation of positive six month results from its STRIDE (Sustained Triamcinolone Release for Inhibition of Diabetic Macular Edema) Phase I Clinical Study. The trial is assessing the safety and tolerability of the I-vation(TM) Intravitreal Implant with triamcinolone acetonide (TA) in patients with Diabetic Macular Edema (DME) under an approved Investigational New Drug application with the U.S. Food and Drug Administration. The data was presented today at the American Society of Retina Specialists (ASRS) meeting in Cannes, France by ASRS President Eugene de Juan, Jr., M.D.
